First in Human Study of AZD9592 in Solid Tumors
← catalyst calendarNCT05647122 · readout in 714 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
167actual
Sites
46
Countries
Australia, Canada, China +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-21 | actual | When the study began enrolling |
| Primary completion | 2028-08-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-03 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumours
- Carcinoma Non-small Cell Lung
- Head and Neck Neoplasms
- Colorectal Neoplasms
Interventions
- Drug: AZD9592
- Drug: Osimertinib
- Drug: 5-Fluorouracil (5-FU)
- Drug: Leucovorin
- Drug: Bevacizumab
Primary outcomes
what the primary-completion date above is the date OFIncidence of Adverse Events (AEs)
measured From time of Informed Consent to 30 days post last dose of AZD9592
Incidence of Serious Adverse Events (SAEs)
measured From time of Informed Consent to 30 days post last dose of AZD9592
Incidence of dose-limiting toxicities (DLT) as defined in the protocol
measured From time of first dose of AZD9592 to end of DLT period (approximately 21 days)
Incidence of baseline laboratory finding, ECG and vital signs changes
measured From time of Informed Consent to 30 days post last dose of AZD9592
Proportion of patients with radiological response (ORR)
measured From date of first dose of AZD9592 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed